20 articles
Amgen expands late-stage testing of its long-acting obesity drug MariTide, including a trial for patients switching from rival GLP-1 medications.
Study shows intensive glucose management increases cardiac stem cells in heart attack patients, potentially improving recovery.
Breakthrough review reveals how modern diabetes treatments protect multiple organs and may extend healthy lifespan through novel mechanisms.
New study suggests Lilly's tirzepatide leads to more lean muscle loss compared to Novo's semaglutide, despite superior weight loss results.
65-patient trial tested bone marrow stem cells injected directly into damaged heart muscle to restore function in chronic heart failure.
A phase 2b trial finds allogeneic MSC infusions improved 6-minute walk distance by 63 meters vs placebo at 9 months in frail older adults.
Pharmaceutical giants clash over obesity drug superiority claims as Lilly's new pill gets FDA approval and Novo fights back with competing data.
Blocking zinc transport in stem cell-derived pancreatic islets improves their survival and function after transplantation for diabetes treatment.
The FDA greenlights a new antibody-drug conjugate for aggressive breast cancer, expanding first-line treatment options for patients.
Eli Lilly suggests lower doses of tirzepatide may safely sustain weight loss at potentially lower cost, opening new options for long-term obesity management.
FDA seeks additional cardiovascular and liver safety data for Eli Lilly's newly approved obesity medication Foundayo.
BioNTech reports positive Phase 2 results for HER2-targeted cancer therapy, with FDA filing planned to compete with existing treatments.
A completed multicenter feasibility trial evaluates BTM, a novel biodegradable scaffold, for treating serious deep burn injuries.
Novel nanogel therapy targets mitochondrial ROS to break the inflammation-hypoxia cycle in periodontitis, showing strong preclinical results.
Mitochondria-targeted antioxidant polymer shows superior protection against liver transplant injury compared to standard treatments.
Breakthrough treatment uses engineered immune cells to eliminate scar tissue and restore liver function in metabolic liver disease.
A Phase 2 trial evaluates MBA-P01, a novel botulinum toxin A, for safety and optimal dosing in treating frown lines.
Scientists discover how tumors use glucose to survive lysosome-blocking drugs, revealing promising combination therapies.
BIIB080 failed its primary endpoint in Phase 2, yet Biogen sees potential signals worth pursuing in the fight against Alzheimer's tau tangles.
Breakthrough crystal technology enables transplanted insulin-producing cells to survive and function for a full year without traditional immunosuppression.
